Progesterone creams: Do they work?

Climacteric

Volumn 6, Issue 3, 2003, Pages 184-187

  Wren, Barry G ^a,b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ROYAL HOSPITAL FOR WOMEN   (Australia)

^c Eastpoint Tower ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PROGESTERONE;

ABSORPTION; ADULT; CANCER RISK; CLINICAL PRACTICE; CREAM; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; EDITORIAL; FEMALE; HORMONE SUBSTITUTION; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MENOPAUSAL SYNDROME; METHODOLOGY; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 0141615915     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/cmt.6.3.184.187     Document Type: Editorial

References (19)

1. Wren BG. Transdermal progesterone or synthetic progestogen. J Br Menopause Soc 2001;7:115-118
2. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-32
3. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J Am Med Assoc 2000;283:485-91
4. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002;288:321-33
5. Lee JR. Use of Pro-Gest cream in postmenopausal women [Letter]. Lancet 1998;352:915
6. Lee JR. Osteoporosis reversal: the role of progesterone. Int Clin Nutr Rev 1990;10:384-9
7. Ferenczy A, Gelfand M, Tzipris F. The cytodynamics of endometrial hyperplasia and carcinoma: a review. Ann Pathol 1983;3:189-98
8. Burger HG. The menopausal transition. In Barlow DH, ed. The Menopause: Key Issues. Baillière's Clin Obstet Gynaecol 1996;10:347-60
9. Wren BG, McFarland K, Edwards L, et al. Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern and plasma progesterone and salivary progesterone levels in postmenopausal women. Climacteric 2000;3:155-60
10. Leonetti HB, Wilson KJ, Anasti JN. Topical progesterone cream has an anti-proliferative effect on estrogen-stimulated endometrium. Fertil Steril 2003;79:221-2
11. Wren BG, Champion SM, Willetts K, et al. Transdermal progesterone and its effects on vasomotor symptoms, blood lipid levels, bone metabolic markers, mood, and quality of life for postmenopausal women. Menopause 2003;10:13-18
12. Burry KA, Patton PE, Hermsmayer K. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen. Am J Obstet Gynaecol 1999;180:1504-11
13. Carey BJ, Carey AH, Patel S, et al. A study to evaluate serum and urinary hormone levels following short and long term administration of two different regimens of progesterone cream in postmenopausal women. Br J Obstet Gynaecol 2000;107:722-26
14. Leonetti HB, Longo S, Anasti JM. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999;94:225-8
15. Devenuto F, Ligon DF, Friedrichsen DH, Wilson HL. Human erythrocyte membrane: uptake of progesterone and chemical alterations. Biochim Biophys Acta 1969;193:36-47
16. Koefoed P, Brahm J. The permeability of the human red cell membrane to steroid sex hormones. Biochim Biophys Acta 1994;1195:55-62
17. Lewis JG, McGill H, Patton VM, Elder PA. Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women. Maturitas 2001;41:1-6
18. Cooper A, Spencer C, Whitehead MI, et al. Systemic absorption of micronised progesterone from Progest cream in postmenopausal women. Lancet 1998;351:1255-6
19. Lee JR, ed. What Your Doctor May Not Tell You About Menopause. New York: Warner Books, 1996